Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 76 to 90 of 166 results for pembrolizumab

  1. Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690

    Awaiting development [GID-TA11073] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development [GID-TA11300] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA779)

    Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.

    Technology appraisal guidance
    Published
    16 March 2022
    View recommendations

    Sections for TA779

  4. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

    Evidence-based recommendations on atezolizumab (Tecentriq) for adjuvant treatment of resected non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    28 September 2022
    View recommendations

    Sections for TA823

  5. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953

    Awaiting development [GID-TA11469] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021

    Awaiting development [GID-TA11556] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer TS ID 11861

    Awaiting development [GID-TA11345] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TS ID 12096]

    Awaiting development [GID-TA11627] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development [GID-TA11137] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pembrolizumab for previously treated multiple myeloma (ID1139)

    Discontinued [GID-TA10193]

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810

    Awaiting development [GID-TA11202] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued [GID-TA10244]

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development [GID-TA11422] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued [GID-TA10418]

    Technology appraisal guidance
    Discontinued

  15. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Awaiting development [GID-TA11338] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development